Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy Bailey

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Assay and Drug Development Technologies|August 14, 2012
The inwardly rectifying potassium channel Kir1.1: development of functional assays to identify and characterize channel inhibitorsJohn P Felix, Birgit T Priest, Kelli Solly, et al.
Nucleic Acids Research|February 10, 2017
Promiscuous DNA-binding of a mutant zinc finger protein corrupts the transcriptome and diminishes cell viabilityKevin R Gillinder, Melissa D Ilsley, Danitza Nébor, et al.
Current Medical Research and Opinion|December 24, 2019
Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitusNick Freemantle, Didac Mauricio, Andrea Giaccari, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 22, 2013
Pharmacologic inhibition of the renal outer medullary potassium channel causes diuresis and natriuresis in the absence of kaliuresisMaria L Garcia, Birgit T Priest, Magdalena Alonso-Galicia, et al.
Bioorganic & Medicinal Chemistry Letters|October 1, 2013
Discovery of a novel sub-class of ROMK channel inhibitors typified by 5-(2-(4-(2-(4-(1H-Tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-oneHaifeng Tang, Reynald K de Jesus, Shawn P Walsh, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of Selective Small Molecule ROMK Inhibitors as Potential New Mechanism DiureticsHaifeng Tang, Shawn P Walsh, Yan Yan, et al.
Bioorganic & Medicinal Chemistry Letters|March 28, 2016
Differentiation of ROMK potency from hERG potency in the phenacetyl piperazine series through heterocycle incorporationShawn P Walsh, Aurash Shahripour, Haifeng Tang, et al.
Journal of Diabetes Science and Technology|April 10, 2013
Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profileRichard M Bergenstal, Andrew J Ahmann, Timothy Bailey, et al.
Diabetes Technology & Therapeutics|March 2, 2013
Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP)Richard M Bergenstal, Andrew J Ahmann, Timothy Bailey, et al.
ACS Medicinal Chemistry Letters|July 21, 2016
Discovery of MK-7145, an Oral Small Molecule ROMK Inhibitor for the Treatment of Hypertension and Heart FailureHaifeng Tang, Yuping Zhu, Nardos Teumelsan, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Assay and Drug Development Technologies|August 14, 2012
The inwardly rectifying potassium channel Kir1.1: development of functional assays to identify and characterize channel inhibitorsJohn P Felix, Birgit T Priest, Kelli Solly, et al.
Nucleic Acids Research|February 10, 2017
Promiscuous DNA-binding of a mutant zinc finger protein corrupts the transcriptome and diminishes cell viabilityKevin R Gillinder, Melissa D Ilsley, Danitza Nébor, et al.
Current Medical Research and Opinion|December 24, 2019
Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitusNick Freemantle, Didac Mauricio, Andrea Giaccari, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 22, 2013
Pharmacologic inhibition of the renal outer medullary potassium channel causes diuresis and natriuresis in the absence of kaliuresisMaria L Garcia, Birgit T Priest, Magdalena Alonso-Galicia, et al.
Bioorganic & Medicinal Chemistry Letters|October 1, 2013
Discovery of a novel sub-class of ROMK channel inhibitors typified by 5-(2-(4-(2-(4-(1H-Tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-oneHaifeng Tang, Reynald K de Jesus, Shawn P Walsh, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of Selective Small Molecule ROMK Inhibitors as Potential New Mechanism DiureticsHaifeng Tang, Shawn P Walsh, Yan Yan, et al.
Bioorganic & Medicinal Chemistry Letters|March 28, 2016
Differentiation of ROMK potency from hERG potency in the phenacetyl piperazine series through heterocycle incorporationShawn P Walsh, Aurash Shahripour, Haifeng Tang, et al.
Journal of Diabetes Science and Technology|April 10, 2013
Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profileRichard M Bergenstal, Andrew J Ahmann, Timothy Bailey, et al.
Diabetes Technology & Therapeutics|March 2, 2013
Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP)Richard M Bergenstal, Andrew J Ahmann, Timothy Bailey, et al.
ACS Medicinal Chemistry Letters|July 21, 2016
Discovery of MK-7145, an Oral Small Molecule ROMK Inhibitor for the Treatment of Hypertension and Heart FailureHaifeng Tang, Yuping Zhu, Nardos Teumelsan, et al.
Pageof 6